Product Images Ziprasidone Mesylate

This is a description of a medication called Ziprasidone Mesylate. It is an injectable solution with a concentration of 20mg/mL available in a small vial. The medication is intended for intramuscular use only and should be stored at controlled room temperature between 20°C to 25°C, with excursions permitted between 15°-30°C. The expiration date is 01/01/2025, and the medication can only be obtained with a prescription. Additional information, including dosage guidelines, can be found in the accompanying prescribing information or the manufacturer's package insert. The medication is produced by HF Acquisition Co., LLC and has an NDC number of 43598-848-58.*

Z'PRASIDONE MESYLATE is a 20mg/mL injection for intramuscular use only. The box contains 10 single-use vials. The NDC number is 51662-1564-3, and the drug expires on January 1, 2025. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F) with permitted excursions to between 15°C to 30°C (59°F to 86°F). The drug must be kept in dry conditions away from light. The manufacturer's package insert should be consulted for further information. The drug is only available with a prescription and is manufactured by HF Acquisition Co., LLC, based in Mukilteo, WA 98275.*

This text contains a boxed warning about the increased risk of mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs. It advises that Ziprasidone mesylate for injection is not approved for treating such patients.*

This is a warning related to the use of antipsychotic drugs on elderly patients with dementia-related psychosis. The warning states that the use of such medications can increase the risk of mortality in this population. The drug Ziprasidone Mesylate for injection specifically mentions that it is not approved for use in this patient population. For more information and complete cautionary details, refer to the full prescribing information.*

Ziprasidone mesylate for injection is a medication that comes in single-dose vials with a concentration of 20 mg/mL. Each carton contains 10 vials. The product's NDC code is NDC-43598-848-58.*

This is a description of a sterile solution for intramuscular use that contains 20mg/mL of ziprasidone mesylate. The solution also includes 4.7mg of methanesulfonic acid and is solubilized by sulfobutylether B-cyclodextrin sodium. The drug is packaged in a single-dose vial and should be stored at controlled room temperature and protected from light. The usual dosage is not specified, but the accompanying prescribing information should provide further details. To prepare the solution, reconstitute to 20 mg/mL using sterile water for injection, shake until dissolved, and a colorless to pale pink solution is formed. The product is manufactured in India.*

The text appears to be a table showing the percentage of patents reporting a ratio. However, the table may be incomplete or corrupted as it only shows the values "0" and "7". Without further context, it is not possible to provide a more detailed description or analysis.*

This is a chart that shows the percentage of patients reporting different adverse reactions to Ziprasidone and Placebo. The adverse reactions are divided into body systems such as cardiovascular, digestive and nervous systems, respiratory, and special senses. It includes both the adverse reaction and the percentage of patients who reported it.*

The text describes the effects of Ziprasidone compared to a placebo, with low doses of 20-40 mg BID and high doses of 60-80 mg BID. It includes weight changes from baseline in kilograms for different sample sizes, as well as the proportion of patients with a greater than 7% increase in weight from baseline for different sample sizes.*